Content area
Full Text
Phakic intraocular lenses (IOLs) provide a safe and effective alternative for patients with myopia who may not be suitable candidates for excimer laser procedures1–4 or for patients who prefer a reversible form of vision correction with efficacy comparable to that of LASIK.5–7
The Visian Implantable Collamer Lens (ICL; STAAR Surgical, Monrovia, Calif) and the Verisyse lens (manufactured by Ophtec [Groningen, The Netherlands] and distributed by Advanced Medical Optics [AMO, Santa Ana, Calif] in the United States) are phakic IOLs that have been approved by the United States Food and Drug Administration (FDA) for the treatment of moderate to severe myopia.
The Visian ICL is a foldable lens made from Collamer, a hydrophilic porcine collagen that produces a soft, ultraviolet light blocking, biocompatible lens.8 Folding of the lens allows insertion through a sutureless 3.0-mm incision. The Visian ICL is designed to be implanted into the posterior chamber behind the iris. The Visian ICL is FDA approved to treat −3.00 to −15.00 diopters (D) of myopia with <2.50 D of astigmatism and is available in powers of −3.00 to −15.50 D of sphere.
The Verisyse lens is made from rigid ultraviolet absorbing polymethylmethacrylate. The lens is inserted into the anterior chamber and is attached to the anterior surface of the iris with haptic clips by enclavation. The rigid nature of the lens requires a 5.5- to 6.5-mm incision, depending on the optic size of the lens. The Verisyse lens is currently FDA approved in two different models: 5-mm optic to treat moderate to severe myopia from −3.00 to −20.00 D in 0.50-D steps with <2.50 D of astigmatism, and 6.0-mm optic for −3.00 to −15.50 D in 0.50-D steps with <2.50 D of astigmatism.
Although large clinical trials have evaluated the Visian ICL and Verisyse lenses independently, no study has yet to directly compare the visual and refractive outcomes of the two lenses. The purpose of this study is to assess postoperative uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), and refractive predictability between the Visian ICL and Verisyse lens. Adverse effects were also evaluated.
Patients and Methods
A retrospective comparative interventional case series was conducted. Thirty consecutive eyes of 16 patients (6 men and 10 women) with a mean age of 39.6...